You have been sucessfully logged out.
Gilead Sciences supports healthcare led initiatives that aim to improve patient care and contribute to advances in medical practice and public health.
As part of this commitment, applications are now open for the Gilead Sciences BENELUX Fellowship Programm. Deadline for submission is 10 September 2026. The program enables healthcare organizations and academic institutions to develop and implement quality improving initiatives across selected therapeutic areas.
In previous years, projects supported through the program have addressed a broad range of healthcare challenges across the BENELUX region. Click here for more information.
Organizations interested in learning more about the program, including eligibility criteria, application procedures (Gilead portal) and contact details of the Gilead Sciences medical manager, can find further information via this link.
With every new medicine, Gilead aims to improve care for millions of patients worldwide living with life-threatening diseases. In addition, Gilead provides financial support through grants to help advance innovative and impactful projects that enhance the quality of care and improve patients’ lives. See the map below for a selection of projects supported through these grants.
Explore the interactive map below
With each new medicine, Gilead aims to improve care for millions of patients worldwide living with life-threatening diseases, including in regions where access to treatment is limited or not yet available.
Gilead Sciences supports organizations working across its key therapeutic areas. The company collaborates with partners to advance its giving mission: improving access to healthcare, reducing barriers faced by underserved populations, and promoting education among healthcare professionals, patients and communities.
Gilead welcomes funding requests for innovative, high-impact projects that address at least one of its core therapeutic areas:
Funding can be requested through the online Grants portal. More information on the application process is available here.
MA-NON-EMEAC-BE-00001